B. Riley FBR analyst Andrew D'Silva initiated coverage of Eton Pharmaceuticals with a Buy rating and $13.50 price target. The company is progressing toward several key commercialization milestones tied to various candidates in its pipeline, D'Silva tells investors in a research note. He points out that s. ET-202, for the treatment of hypotension during epidural and spinal anesthesia, and ET-105, an oral liquid formulation of lamotrigine for epilepsy treatment, have FDA action dates scheduled for October 2019 and March 2020, respectively. The analyst sees near-term catalysts for the shares.